Skip to content
Search

Latest Stories

Vision for Pharmacy Professional Practice becoming a reality: RPS publishes one year on report

Vision for Pharmacy Professional Practice becoming a reality: RPS publishes one year on report

The publication of the NHS Long Term Workforce Plan is identified as one of the key milestones achieved since the launch of the vision 

The Royal Pharmaceutical Society (RPS) in England has published a review of its 10-year Vision for Pharmacy Professional Practice that was launched in December 2022 in collaboration with The King’s Fund.


The ‘one year on’ vision report highlighted key milestones achieved in the first 12 months since its publication as well as opportunities for further progress.

It identified the publication of the NHS Long Term Workforce Plan, which recognises the significant role that pharmacists play in healthcare and commits to growing and expanding the pharmacy workforce, as one of the positive policy developments made since the launch of the vision.

The development of a Vision for Community Pharmacy by Community Pharmacy England, the Nuffield Trust and The King’s Fund; work on digital integration to enable community pharmacists to update a clinical record; the launch of Pharmacy First scheme; and the publication of the public consultation of pharmacy supervision were other key milestones mentioned in the report.

Tase Oputu, Chair of the RPS's English Pharmacy Board, agreed that significant progress has been made in the last 12 months, but also emphasised that there is still more to do to “transform, unlock and enable the full breadth of opportunities for pharmacy teams.”

She said: “Additional investment in the community pharmacy sector, development of prescribing pilots, and further digital integrations are just some examples of the vision becoming a reality.

“There has been some fantastic work across the profession, as well as collaboration with pharmacy organisations, professional bodies and others to drive this forward.”

Oputu added that workforce shortages continue to pose a significant challenge in the pharmacy sector, combined with a constrained funding model.

The report noted that these challenges have resulted in closures, subsequently reducing patient accessibility in certain areas.

RPS Director for England, James Davies commented: “The development of RPS policy on separation of dispensing and prescribing helps to move forward our Vision for professional practice.

“The RPS has continued to highlight the pressures that pharmacy teams face and campaigned to remove the prescription charges that contribute to health inequalities.

“We have made some positive progress in 2023, but there is still much to be done across all sectors of practice to help make this vision a reality for patients.”

The report is structured around the six main themes identified in the Vision, which are:

  1. Supporting people and communities to live well for longer
  2. Enabling people to live well with the medicines that they take
  3. Enhancing patient experience and access to care
  4. Our pharmacy people
  5. Data, innovation, science and research
  6. Leadership, collaboration and integration

“The profession is making progress in the right direction, but continued and sustained action is needed,” the report added.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less